Focused On-demand Library for Zinc transporter ZIP5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q6ZMH5

UPID:

S39A5_HUMAN

Alternative names:

Solute carrier family 39 member 5; Zrt- and Irt-like protein 5

Alternative UPACC:

Q6ZMH5; B2R808; Q8N6Y3

Background:

Zinc transporter ZIP5, also known as Solute carrier family 39 member 5 and Zrt- and Irt-like protein 5, plays a crucial role in zinc and copper homeostasis. It facilitates the transport of zinc(2+) into cells and is involved in zinc excretion from the intestine. Additionally, ZIP5 has been shown to regulate glucose-stimulated insulin secretion through the zinc-activated SIRT1-PPARGC1A axis and modulate the BMP/TGF-beta signaling pathway, impacting eye development and the extracellular matrix of the sclera.

Therapeutic significance:

ZIP5's involvement in Myopia 24, autosomal dominant, underscores its therapeutic potential. Understanding the role of Zinc transporter ZIP5 could open doors to potential therapeutic strategies, particularly in managing myopia and disorders related to zinc and copper metabolism.